Pentraxin 3 is a marker of early joint inflammation in patients with juvenile idiopathic arthritis

Immunologic Research

Volumn 56, Issue 2-3, 2013, Pages 444-450

  Padeh, Shai ^a,b   Farzam, Nahid ^a,b   Chayen, Gilad ^a,b   Gerstein, Maya ^a,b   Berkun, Yackov ^a,b,c  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Children; DMARD disease modifying antirheumatic drugs; Intra articular corticosteroid injection; Juvenile idiopathic arthritis; Pentraxin 3

Indexed keywords

ANTINUCLEAR ANTIBODY; C REACTIVE PROTEIN; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; INTERLEUKIN 1; INTERLEUKIN 6; METHOTREXATE; PENTRAXIN 3; RHEUMATOID FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR INHIBITOR;

ADOLESCENT; ARTICLE; CELL STIMULATION; CHILD; COHORT ANALYSIS; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; IN VITRO STUDY; JOINT ASPIRATION; JOINT SWELLING; JUVENILE RHEUMATOID ARTHRITIS; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; PROTEIN SECRETION; REMISSION; SCHOOL CHILD; SYNOVIAL FLUID; SYNOVIOCYTE;

ADOLESCENT; ARTHRITIS, JUVENILE; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CELL LINE; CHILD; CHILD, PRESCHOOL; CYTOKINES; DISEASE PROGRESSION; EARLY DIAGNOSIS; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION; HUMANS; INFANT; MALE; PROGNOSIS; PROSPECTIVE STUDIES; SERUM AMYLOID P-COMPONENT; SYNOVIAL MEMBRANE;

EID: 84879553664     PISSN: 0257277X     EISSN: 15590755     Source Type: Journal    
DOI: 10.1007/s12026-013-8417-8     Document Type: Article

References (28)

1. Borchers A, Selmi C, Cheema G, Keen C, Shoenfeld Y, Gershwin ME. Juvenile idiopathic arthritis. Autoimmun Rev. 2006;5:279-98. (Pubitemid 44269021)
2. Berkun Y, Padeh S. Environmental factors and the geoepidemiology of juvenile idiopathic arthritis. Autoimmun Rev. 2010;9:A319-24.
3. Mayerl C, Prelog M. Immunosenescence and juvenile idiopathic arthritis. Autoimmun Rev. 2010;11:297-300.
4. Lin YT, Wang CT, Gershwin ME, Chiang BL. The pathogenesis of oligoarticular/polyarticular vs systemic juvenile idiopathic arthritis. Autoimmun Rev. 2011;10:482-9.
5. Introna M, Alles VV, Castellano M, Picardi G, De Gioia L, Bottazzai B, et al. Cloning of mouse ptx3, a new member of the pentraxin gene family expressed at extrahepatic sites. Blood. 1996;87:1862-72. (Pubitemid 26068902)
6. Coe JE, Margossian SS, Slayter HS, Sogn JA. Hamster female protein. A new Pentraxin structurally and functionally similar to C-reactive protein and amyloid P component. J Exp Med. 1981;153:977-91. (Pubitemid 11104744)
7. Mold C, Baca R, Du Clos T. W. Serum amyloid P component and C-reactive protein opsonize apoptotic cells for phagocytosis through Fcγ receptors. J Autoimmun. 2002;19:147-54. (Pubitemid 35341864)
8. Szalai AJ, van Ginkel FW, Wang Y, McGhee JR, Volanakis JE. Complement dependent acute-phase expression of C-reactive protein and serum amyloid Pcomponent. J Immunol. 2000;165:1030-5. (Pubitemid 30484773)
9. Gewurz H, Zhang XH, Lint TF. Structure and function of the pentraxins. Curr Opin Immunol. 1995;7:54-64.
10. Bottazzi B, Garlanda C, Salvatori G, Jeannin P, Manfredi A, Mantovani A. Pentraxins as a key component of innate immunity. Curr Opin Immunol. 2006;18:10-5. (Pubitemid 43049642)
11. Breviario F, d'Aniello EM, Golay J, Peri G, Bottazzi B, Bairoch A, et al. Interleukin-1-inducible genes in endothelial cells. Cloning of a new gene related to C-reactive protein and serum amyloid P component. J Biol Chem. 1992;267:22190-7.
12. Maina V, Cotena A, Doni A, Nebuloni M, Pasqualini F, Milner CM, et al. Coregulation in human leukocytes of the long pentraxin PTX3 and TSG-6. J Leukoc Biol. 2009;86:123-32.
13. Luchetti MM, Piccinini G, Mantovani A, Peri G, Matteucci C, Pomponio G, et al. Expression and production of the long pentraxin PTX3 in rheumatoid arthritis (RA). Clin Exp Immunol. 2000;119:196-202. (Pubitemid 30064610)
14. Bevelacqua Bevelacqua V, Libra M, Mazzarino MC, Gangemi P, Nicotra G, Curatolo S, et al. Long pentraxin 3: a marker of inflammation in untreated psoriatic patients. Int J Mol Med. 2006;18:415-23.
15. Bussolati B, Peri G, Salvidio G, Verzola D, Mantovani A, Gamuss G. The long pentraxin PTX3 is synthesized in IgA glomerulonephritis and activates mesangial cells. J Immunol. 2003;170:1466-72. (Pubitemid 36139516)
16. Hollan I, Bottazzi B, Cuccovillo I, Førre ØT, Mikkelsen K, Saatvedt K et al. Increased levels of serum pentraxin 3, a novel cardiovascular biomarker, in patients with inflammatory rheumatic disease. Arthritis Care Res. 2010;62:378-85.
17. Sciascia S, Ceberio L, Garcia-Fernandez C, Roccatello D, Karim Y, Cuadrado MJ. Systemic lupus erythematosus and infections: clinical importance of conventional and upcoming biomarkers. Autoimmun Rev. 2012;12:157-63.
18. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31:390-2. (Pubitemid 38160763)
19. Amariglio N, Klein A, Dagan L, Lev A, Padeh S, Rechavi G, et al. T-cell compartment in synovial fluid of pediatric patients with JIA correlates with disease phenotype. J Clin Immunol. 2011;31:1021-8.
20. Wallace CA, Ravelli A, Huang B, Giannini EH. Preliminary validation of clinical remission criteria using the OMERACT filter for select categories of juvenile idiopathic arthritis. J Rheumatol. 2006;33:789-95.
21. Padeh S, Pinhas-Hamiel O, Zimmermann-Sloutskis D, Berkun Y. Children with oligoarticular juvenile idiopathic arthritis are at considerable risk for growth retardation. J Pediatr. 2011;159:832-7.
22. Guillaume S, Prieur AM, Coste J, Job-Deslandre C. Long-term outcome and prognosis in oligoarticular-onset juvenile idiopathic arthritis. Arthritis Rheum. 2000;43:1858-65. (Pubitemid 30640942)
23. Chen KRSM, Ikemoto K, Abe R, Shimizu H. Granulomatous arteritis in cutaneous lesions of Churg-Strauss syndrome. J Cutan Pathol. 2007;34:330-7. (Pubitemid 46466096)
24. Yamazaki T, Yokoyama T, Akatsu H, Tukiyama T, Tokiwa T. Phenotypic characterization of a human synovial sarcoma cell line, SW982, and its response to dexamethasone. In vitro cellular & developmental biology. 2003;39:337-9. (Pubitemid 38420338)
25. Berkun Y, Bendersky A, Gerstein M, Goldstein I, Padeh S, Bank I. GammadeltaT cells in juvenile idiopathic arthritis: higher percentages of synovial Vdelta1 + and Vgamma9 + T cell subsets are associated with milder disease. J Rheumatol. 2011;38:1123-9.
26. Bendersky A, Marcu-Malina V, Berkun Y, Gerstein M, Nagar M, Goldstein I, et al. Cellular interactions of synovial fluid gammadelta T cells in juvenile idiopathic arthritis. J Immunol. 2012;188:4349-59.
27. Grom AA, Murray KJ, Luyrink L, Emery H, Passo MH, Glass DN, et al. Patterns of expression of tumor necrosis factor alpha, tumor necrosis factor beta, and their receptors in synovia of patients with juvenile rheumatoid arthritis and juvenile spondylarthropathy. Arthritis Rheum. 1996;39:1703-10. (Pubitemid 26331024)
28. Muller BPG, Doni A, Torri V, Landmann R, Bottazzi B, Mantovani A. Circulating levels of the long pentraxin PTX3 correlate with severity of infection in critically ill patients. Crit Care Med. 2001;29:1404-7. (Pubitemid 32641804)